Company intelligence / Profile preview
Hemab Therapeutics
Cambridge, Massachusetts, United Stateshemab.com ↗
- Ownership
- Private
- Employees
- ~15
- Development stage
- Other
01
Overview
Hemab Therapeutics develops first-in-class prophylactic antibody therapies targeting rare and underserved bleeding and thrombotic disorders. Their lead program, HMB-002, a monovalent human antibody targeting the C-terminal CK domain of VWF for Von Willebrand Disease, aims to boost endogenous VWF levels without impairing function. Preclinical data show promising therapeutic potential. The company pursues a strategic "1–2–5" plan to develop five clinical assets by 2025 addressing multiple rare blood clotting diseases[1][3][5].
- Therapeutic areas
- HematologyRare Diseases
- Modalities
- Monoclonal antibodiesBispecific antibodies
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Hemab Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hemab Therapeutics.